On August 29, 2024 Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, reported participation in three upcoming investor conferences (Press release, Ultragenyx Pharmaceutical, AUG 29, 2024, View Source [SID1234646211]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Morgan Stanley 22nd Annual Global Healthcare Conference (New York, NY)
Wednesday, September 4, 2024, Emil Kakkis, M.D., Ph.D., CEO and President, will participate in a fireside chat and host 1×1 meetings.
Cantor Global Healthcare Conference (New York, NY)
Tuesday, September 17, 2024, Emil Kakkis and Howard Horn, Chief Financial Officer, will participate in a fireside chat and host 1×1 meetings.
Bank of America Global Healthcare Conference (London, UK)
Wednesday, September 18, 2024, Eric Crombez, M.D., Chief Medical Officer and Joshua Higa, Vice President, Investor Relations, will participate in a fireside chat and host 1×1 meetings.
The live and archived webcast of the fireside chats will be accessible from the company’s website at View Source